BRIEF-Maxeon Announces Restructuring Of Business Portfolio-March 2024-www.financetom.com

BRIEF-Maxeon Announces Restructuring Of Business Portfolio

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Maxeon Announces Restructuring Of Business Portfolio

Nov 26, 2024 5:26 AM

Nov 26 (Reuters) - Maxeon Solar Technologies Ltd ( MAXN )

* MAXEON ANNOUNCES RESTRUCTURING OF BUSINESS PORTFOLIO

* MAXEON SOLAR TECHNOLOGIES LTD ( MAXN ) - TO FOCUS EXCLUSIVELY ON

U.S.

MARKET

* MAXEON SOLAR TECHNOLOGIES LTD ( MAXN ) - AGREES TO SELL EMEA, APAC,

LATAM

SALES TO TCL GROUP

* MAXEON SOLAR TECHNOLOGIES LTD ( MAXN ) - TCL GROUP TO ACQUIRE

MAXEON'S

PHILIPPINES MANUFACTURING OPERATIONS

* MAXEON SOLAR TECHNOLOGIES LTD ( MAXN ) - LEASES BUILDING IN

ALBUQUERQUE

FOR 2 GW SOLAR PANEL MANUFACTURING

Source text:

Further company coverage:

Previous page： Next page： Roche to complete acquisition of U.S. biopharma company Poseida

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Jan 7, 2025

...

Roche to complete acquisition of U.S. biopharma company Poseida

Jan 7, 2025

ZURICH, Jan 8 (Reuters) - Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics via its subsidiary Blue Giant Acquisition Corp. Roche said it has accepted for payment nearly 65 million shares in Poseida - equivalent to 66% of the California company's stock - which had been tendered by shareholders at a price...

BRIEF-Roche Purchases Shares Of Poseida Therapeutics, Inc. In Tender Offer

Jan 7, 2025

Jan 8 (Reuters) - ROCHE HOLDING AG: * ROCHE PURCHASES SHARES IN TENDER OFFER FOR POSEIDA THERAPEUTICS, INC. * ACCEPTS PAYMENT FOR POSEIDA SHARES AT $9.00 PER SHARE PLUS CVR * TENDER OFFER EXPIRED ON 7 JANUARY 2025, WAS NOT EXTENDED * APPROXIMATELY 64,991,586 SHARES OF POSEIDA TENDERED, REPRESENTING 66.11% OF OUTSTANDING SHARES * FOLLOWING COMPLETION OF MERGER, POSEIDA WILL...

Roche to complete $1.5 billion acquisition of U.S. biopharma company Poseida

Jan 7, 2025

ZURICH (Reuters) -Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics , a specialist in complex immune cell therapies to treat several types of blood cancer. Roche said it has accepted for payment nearly 65 million shares in Poseida - equivalent to 66% of the California company's stock - which had been tendered...